title: Population pharmacokinetics of glyburide in patients with well-controlled diabetes.
abstract: OBJECTIVE
  To investigate glyburide pharmacokinetics in patients with well-controlled noninsulin-dependent diabetes mellitus (NIDDM), and test the hypothesis that intersubject variability in the glyburide dose is due to patient differences in the drug's pharmacokinetics.
  
  
  METHODS
  Prospective, open-label study.
  
  
  METHODS
  University-affiliated, internal medicine outpatient clinic.
  
  
  METHODS
  Fifty-one patients with NIDDM (11 women, 40 men, mean age 56.7 +/- 15.3 yrs) receiving oral glyburide and with well-controlled glycohemoglobin levels 10.0% or below.
  
  
  METHODS
  After fasting overnight, patients ingested their regular morning dose of glyburide and then ate breakfast. Blood samples were drawn before dosing and between 0.5-2 hours, 2-5 hours, and 5-10 hours after dosing.
  
  
  RESULTS
  Serum glyburide was assayed by high-performance liquid chromatography and pharmacokinetics by NONMEM. Glyburide clearance was proportional to weight and greater in older patients (> 60 yrs).
  
  
  CONCLUSIONS
  Variability in the glyburide dose was not primarily due to intersubject differences in the drug's pharmacokinetics.
authors.affiliation: Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha 68198-6025, USA.
authors.forename: W G
authors.initials: WG
authors.lastname: Tracewell
authors.forename: D J
authors.initials: DJ
authors.lastname: Stalker
authors.forename: P A
authors.initials: PA
authors.lastname: Maloley
authors.forename: T F
authors.initials: TF
authors.lastname: Gallagher
authors.forename: P R
authors.initials: PR
authors.lastname: Gwilt
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001682:Biological Availability; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D005905:Glyburide / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D007004:Hypoglycemic Agents; D005905:Glyburide